Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220021/S009

DETOUR System

Endologix, LLC · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONP220021/S009

What did the FDA decide?

The FDA record for P220021/S009, titled "DETOUR System" with the decision code OK30 and dated 2026-10-16, lists this action as a 30-Day Notice under the supplement reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The reported statement describes approval for changes to visual acceptance criteria for TORUS SGDS Latch and Pulley Subassembly components. The record does not explain what those criteria are, what the prior criteria specified, or how the subassembly is manufactured, so those details remain absent from the supplied fields.

The P220021 identifier alone establishes the parent PMA relationship; it does not show that the full DETOUR System was newly approved. The product code QWM, the superficial femoral artery stent graft category, and the applicant Endologix, LLC, appear in the supplied fields. The stated purpose concerns visual acceptance criteria, not proof of safety or clinical effectiveness, and none of the supplied fields report trial data or clinical outcomes.

FDA approval order statement

approval for changes to visual acceptance criteria for TORUS SGDS Latch and Pulley Subassembly components
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220021/S009
Regulatory pathway
PMA supplement
Product code
QWM
Decision code
OK30
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent graft, bypass, superficial femoral artery.

Product code
QWM
FDA device class
3

For the original device and its historical approval scope, see PMA P220021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220021/S009 received

    Application receipt date recorded by FDA.

  2. P220021/S009 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P220021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220021

Product / regulatory recordCompanyPathwayDecision dateSource
Endologix, LLCPMA approvalJun 7, 2023FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endologix, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3910 Brickway Blvd., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records